185 related articles for article (PubMed ID: 31651720)
1. Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.
Suarez-Kurtz G; Araújo GS; de Sousa SJ
Pharmacogenet Genomics; 2020 Jan; 30(1):1-4. PubMed ID: 31651720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon.
Ferreira GMA; Ribeiro Elias AB; Nascimento J; Monteiro WM; Melo GC; Baia-da-Silva DC; Lacerda MVG; Suarez-Kurtz G
Pharmacogenet Genomics; 2020 Oct; 30(8):184-189. PubMed ID: 32453263
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.
Sutiman N; Chen S; Ling KL; Chuah SW; Leong WF; Nadiger V; Tjai M; Choon Kong CS; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Cheung YB; Chowbay B
Pharmacogenomics; 2018 Jan; 19(1):31-43. PubMed ID: 29210335
[TBL] [Abstract][Full Text] [Related]
6. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity.
Shah SAV; Paradkar MU; Desai DC; Ashavaid TF
Drug Metab Pers Ther; 2018 Mar; 33(1):57-60. PubMed ID: 29470173
[TBL] [Abstract][Full Text] [Related]
7. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
8. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
Walker GJ; Harrison JW; Heap GA; Voskuil MD; Andersen V; Anderson CA; Ananthakrishnan AN; Barrett JC; Beaugerie L; Bewshea CM; Cole AT; Cummings FR; Daly MJ; Ellul P; Fedorak RN; Festen EAM; Florin TH; Gaya DR; Halfvarson J; Hart AL; Heerasing NM; Hendy P; Irving PM; Jones SE; Koskela J; Lindsay JO; Mansfield JC; McGovern D; Parkes M; Pollok RCG; Ramakrishnan S; Rampton DS; Rivas MA; Russell RK; Schultz M; Sebastian S; Seksik P; Singh A; So K; Sokol H; Subramaniam K; Todd A; Annese V; Weersma RK; Xavier R; Ward R; Weedon MN; Goodhand JR; Kennedy NA; Ahmad T;
JAMA; 2019 Feb; 321(8):773-785. PubMed ID: 30806694
[TBL] [Abstract][Full Text] [Related]
9. The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs.
von Muhlenbrock C; Estay C; Covarrubias N; Miranda J; Venegas M
Pharmacogenet Genomics; 2023 Sep; 33(7):161-163. PubMed ID: 37556121
[TBL] [Abstract][Full Text] [Related]
10.
Perini JA; Basta PC; Suarez-Kurtz G
Front Pharmacol; 2024; 15():1359570. PubMed ID: 38379902
[TBL] [Abstract][Full Text] [Related]
11. Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Texis T; Guzmán-Cruz C; Rodríguez-Dorantes M; Sánchez-García S; Mino-León D; Gonzalez-Covarrubias V
Pharmacol Rep; 2022 Feb; 74(1):257-262. PubMed ID: 34091879
[TBL] [Abstract][Full Text] [Related]
12. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results.
Dickson AL; Daniel LL; Zanussi J; Dale Plummer W; Wei WQ; Liu G; Reese T; Anandi P; Birdwell KA; Kawai V; Cox NJ; Dupont WD; Hung AM; Feng Q; Stein CM; Chung CP
Clin Pharmacol Ther; 2022 Jan; 111(1):263-271. PubMed ID: 34582038
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
14. Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation.
Díaz-Villamarín X; Fernández-Varón E; Rojas Romero MC; Callejas-Rubio JL; Cabeza-Barrera J; Rodríguez-Nogales A; Gálvez J; Morón R
Biomed Pharmacother; 2023 Dec; 168():115706. PubMed ID: 37857254
[TBL] [Abstract][Full Text] [Related]
15. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.
Grover N; Bhatia P; Kumar A; Singh M; Lad D; Mandavdhare HS; Samanta J; Prasad KK; Dutta U; Sharma V
BMC Gastroenterol; 2021 Aug; 21(1):327. PubMed ID: 34425754
[TBL] [Abstract][Full Text] [Related]
16. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
18. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
[TBL] [Abstract][Full Text] [Related]
19. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
Banerjee R; Ravikanth VV; Pal P; Bale G; Avanthi US; Goren I; Girish BG; Mitnala S; Reddy DN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1683-1694. PubMed ID: 33111378
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients.
Shah SA; Paradkar M; Desai D; Ashavaid TF
J Gastroenterol Hepatol; 2017 Mar; 32(3):620-624. PubMed ID: 27416873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
